Back to search
FDAFDA · Food and drugs·Recall number D-237-2013

CLONAZEPAM ORALLY DISINTERGRATING Tablets, USP, 0.5 mg, 60 tablets (10 blister cards of 6 tablets each), TEVA PHARMACEUTICALS USA, Sellersville PA 18960, NDC #0555-0096-96

Published April 10, 2013 · Recall initiated: February 7, 2013

Summary

FDA records drug Class II recall D-237-2013, published April 10, 2013 and initiated February 7, 2013. Recalling firm: Teva Pharmaceuticals USA, Inc.; Status: Terminated; Reported quantity: 3 boxes; Lot: Lot # 32900136A, Exp. 05/14. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Content Uniformity Specifications: Recall is being carried out due to an out-of-specification result for content uniformity.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA, Inc.
Distributor
NC
Lot
Lot # 32900136A, Exp. 05/14
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was CLONAZEPAM ORALLY DISINTERGRATING Tablets, USP, 0.5 mg, 60 tablets (10 blister cards of 6 tablets each), TEVA PHARMACEUTICALS USA, Sellersville PA 18960, NDC #0555-0096-96 recalled?

Yes. FDA published recall D-237-2013 on April 10, 2013. Reported hazard: Failed Content Uniformity Specifications: Recall is being carried out due to an out-of-specification result for content uniformity.

What should I do if I have this product?

Voluntary: Firm initiated · Letter